APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Multivalent Vaccines Market Analysis and Forecast 2026-2032

26 December 2025190 pages

Choose your research edition.

Industry ResearchMultivalent Vaccines Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Vaccines Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Multivalent Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Vaccines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Multivalent Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Multivalent Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Multivalent Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Multivalent Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Multivalent Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Multivalent Vaccines include Bavarian Nordic (Denmark), CSL Limited (Australia), Daiichi Sankyo (Japan), Emergent BioSolutions, Inc(US), GlaxoSmithKline, plc (U.K.), MedImmune, LLC (US), Mitsubishi Tanabe Pharma Corporation (Japan), Panacea Biotec (India) and Protein Sciences Corporation (US), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Multivalent Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Multivalent Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Multivalent Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multivalent Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Multivalent Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Multivalent Vaccines sales, projected growth trends, production technology, application and end-user industry.

Multivalent Vaccines Segment by Company

Bavarian Nordic (Denmark)

CSL Limited (Australia)

Daiichi Sankyo (Japan)

Emergent BioSolutions, Inc(US)

GlaxoSmithKline, plc (U.K.)

MedImmune, LLC (US)

Mitsubishi Tanabe Pharma Corporation (Japan)

Panacea Biotec (India)

Protein Sciences Corporation (US)

Serum Institute of India Pvt. Ltd. (India)

Astellas Pharma Inc. (Japan)

Pfizer, Inc(US)

Merck & Co., Inc(US)

Johnson & Johnson (US)

Sanofi Pasteur SA (France)

Multivalent Vaccines Segment by Type

Toxoid Vaccines

Live Attenuated Vaccines

Conjugate Vaccines

Inactivated and Subunit Vaccines

Recombinant Vaccines

Multivalent Vaccines Segment by Application

Pediatrics

Adults

Multivalent Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Multivalent Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multivalent Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Multivalent Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Toxoid Vaccines Major Manufacturers Table 3. Live Attenuated Vaccines Major Manufacturers Table 4. Conjugate Vaccines Major Manufacturers Table 5. Inactivated and Subunit Vaccines Major Manufacturers Table 6. Recombinant Vaccines Major Manufacturers Table 7. Global Multivalent Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Pediatrics Major Manufacturers Table 9. Adults Major Manufacturers Table 10. Multivalent Vaccines Industry Trends Table 11. Multivalent Vaccines Industry Drivers Table 12. Multivalent Vaccines Industry Opportunities and Challenges Table 13. Multivalent Vaccines Industry Restraints Table 14. Global Multivalent Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Multivalent Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Multivalent Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Multivalent Vaccines Revenue Market Share by Region (2021-2026) Table 18. Global Multivalent Vaccines Revenue Market Share by Region (2027-2032) Table 19. Global Multivalent Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 20. Global Multivalent Vaccines Sales by Region (2021-2026) & (W Units) Table 21. Global Multivalent Vaccines Sales by Region (2027-2032) & (W Units) Table 22. Global Multivalent Vaccines Sales Market Share by Region (2021-2026) Table 23. Global Multivalent Vaccines Sales Market Share by Region (2027-2032) Table 24. Global Multivalent Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Multivalent Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Multivalent Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Multivalent Vaccines Sales Market Share by Manufacturers (2021-2026) Table 28. Global Multivalent Vaccines Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Multivalent Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Multivalent Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Multivalent Vaccines Manufacturers, Product Type & Application Table 32. Global Multivalent Vaccines Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Multivalent Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Multivalent Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Multivalent Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Multivalent Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Multivalent Vaccines Revenue Market Share by Type (2021-2026) Table 39. Global Multivalent Vaccines Revenue Market Share by Type (2027-2032) Table 40. Global Multivalent Vaccines Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 41. Global Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 42. Global Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 43. Global Multivalent Vaccines Sales Market Share by Type (2021-2026) Table 44. Global Multivalent Vaccines Sales Market Share by Type (2027-2032) Table 45. Global Multivalent Vaccines Price by Type (2021-2026) & (US$/Unit) Table 46. Global Multivalent Vaccines Price by Type (2027-2032) & (US$/Unit) Table 47. Global Multivalent Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Multivalent Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Multivalent Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Multivalent Vaccines Revenue Market Share by Application (2021-2026) Table 51. Global Multivalent Vaccines Revenue Market Share by Application (2027-2032) Table 52. Global Multivalent Vaccines Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 53. Global Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 54. Global Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 55. Global Multivalent Vaccines Sales Market Share by Application (2021-2026) Table 56. Global Multivalent Vaccines Sales Market Share by Application (2027-2032) Table 57. Global Multivalent Vaccines Price by Application (2021-2026) & (US$/Unit) Table 58. Global Multivalent Vaccines Price by Application (2027-2032) & (US$/Unit) Table 59. Bavarian Nordic (Denmark) Company Information Table 60. Bavarian Nordic (Denmark) Business Overview Table 61. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio Table 63. Bavarian Nordic (Denmark) Recent Development Table 64. CSL Limited (Australia) Company Information Table 65. CSL Limited (Australia) Business Overview Table 66. CSL Limited (Australia) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. CSL Limited (Australia) Multivalent Vaccines Product Portfolio Table 68. CSL Limited (Australia) Recent Development Table 69. Daiichi Sankyo (Japan) Company Information Table 70. Daiichi Sankyo (Japan) Business Overview Table 71. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio Table 73. Daiichi Sankyo (Japan) Recent Development Table 74. Emergent BioSolutions, Inc(US) Company Information Table 75. Emergent BioSolutions, Inc(US) Business Overview Table 76. Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio Table 78. Emergent BioSolutions, Inc(US) Recent Development Table 79. GlaxoSmithKline, plc (U.K.) Company Information Table 80. GlaxoSmithKline, plc (U.K.) Business Overview Table 81. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio Table 83. GlaxoSmithKline, plc (U.K.) Recent Development Table 84. MedImmune, LLC (US) Company Information Table 85. MedImmune, LLC (US) Business Overview Table 86. MedImmune, LLC (US) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. MedImmune, LLC (US) Multivalent Vaccines Product Portfolio Table 88. MedImmune, LLC (US) Recent Development Table 89. Mitsubishi Tanabe Pharma Corporation (Japan) Company Information Table 90. Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview Table 91. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio Table 93. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development Table 94. Panacea Biotec (India) Company Information Table 95. Panacea Biotec (India) Business Overview Table 96. Panacea Biotec (India) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Panacea Biotec (India) Multivalent Vaccines Product Portfolio Table 98. Panacea Biotec (India) Recent Development Table 99. Protein Sciences Corporation (US) Company Information Table 100. Protein Sciences Corporation (US) Business Overview Table 101. Protein Sciences Corporation (US) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio Table 103. Protein Sciences Corporation (US) Recent Development Table 104. Serum Institute of India Pvt. Ltd. (India) Company Information Table 105. Serum Institute of India Pvt. Ltd. (India) Business Overview Table 106. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio Table 108. Serum Institute of India Pvt. Ltd. (India) Recent Development Table 109. Astellas Pharma Inc. (Japan) Company Information Table 110. Astellas Pharma Inc. (Japan) Business Overview Table 111. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio Table 113. Astellas Pharma Inc. (Japan) Recent Development Table 114. Pfizer, Inc(US) Company Information Table 115. Pfizer, Inc(US) Business Overview Table 116. Pfizer, Inc(US) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Pfizer, Inc(US) Multivalent Vaccines Product Portfolio Table 118. Pfizer, Inc(US) Recent Development Table 119. Merck & Co., Inc(US) Company Information Table 120. Merck & Co., Inc(US) Business Overview Table 121. Merck & Co., Inc(US) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio Table 123. Merck & Co., Inc(US) Recent Development Table 124. Johnson & Johnson (US) Company Information Table 125. Johnson & Johnson (US) Business Overview Table 126. Johnson & Johnson (US) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Johnson & Johnson (US) Multivalent Vaccines Product Portfolio Table 128. Johnson & Johnson (US) Recent Development Table 129. Sanofi Pasteur SA (France) Company Information Table 130. Sanofi Pasteur SA (France) Business Overview Table 131. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio Table 133. Sanofi Pasteur SA (France) Recent Development Table 134. North America Multivalent Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 135. North America Multivalent Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 136. North America Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 137. North America Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 138. North America Multivalent Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 139. North America Multivalent Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 140. North America Multivalent Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Multivalent Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 143. North America Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 144. North America Multivalent Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 145. North America Multivalent Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 146. North America Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Multivalent Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. North America Multivalent Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. North America Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 150. North America Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 151. North America Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 152. North America Multivalent Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 153. North America Multivalent Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 154. United States Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 155. Canada Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 156. Mexico Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 157. Europe Multivalent Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe Multivalent Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 160. Europe Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 161. Europe Multivalent Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 162. Europe Multivalent Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 163. Europe Multivalent Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 164. Europe Multivalent Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 165. Europe Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 166. Europe Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 167. Europe Multivalent Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 168. Europe Multivalent Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 169. Europe Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Europe Multivalent Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Europe Multivalent Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Europe Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 173. Europe Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 174. Europe Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 175. Europe Multivalent Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 176. Europe Multivalent Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 177. Germany Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 178. France Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 179. U.K. Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 180. Italy Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 181. Russia Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 182. Spain Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 183. Netherlands Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 184. Switzerland Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 185. Sweden Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 186. Poland Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 187. China Multivalent Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 188. China Multivalent Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 189. China Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 190. China Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 191. China Multivalent Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 192. China Multivalent Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 193. China Multivalent Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 194. China Multivalent Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 195. China Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 196. China Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 197. China Multivalent Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 198. China Multivalent Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 199. Asia Multivalent Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 200. Asia Multivalent Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 201. Asia Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 202. Asia Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 203. Asia Multivalent Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 204. Asia Multivalent Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 205. Asia Multivalent Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 206. Asia Multivalent Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 207. Asia Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 208. Asia Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 209. Asia Multivalent Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 210. Asia Multivalent Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 211. Asia Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. Asia Multivalent Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. Asia Multivalent Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. Asia Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 215. Asia Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 216. Asia Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 217. Asia Multivalent Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 218. Asia Multivalent Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 219. Japan Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 220. South Korea Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 221. India Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 222. Australia Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 223. Taiwan Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 224. Southeast Asia Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 225. SAMEA Multivalent Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 226. SAMEA Multivalent Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 227. SAMEA Multivalent Vaccines Sales by Type (2021-2026) & (W Units) Table 228. SAMEA Multivalent Vaccines Sales by Type (2027-2032) & (W Units) Table 229. SAMEA Multivalent Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 230. SAMEA Multivalent Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 231. SAMEA Multivalent Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 232. SAMEA Multivalent Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 233. SAMEA Multivalent Vaccines Sales by Application (2021-2026) & (W Units) Table 234. SAMEA Multivalent Vaccines Sales by Application (2027-2032) & (W Units) Table 235. SAMEA Multivalent Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 236. SAMEA Multivalent Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 237. SAMEA Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 238. SAMEA Multivalent Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 239. SAMEA Multivalent Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 240. SAMEA Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 241. SAMEA Multivalent Vaccines Sales by Country (2021-2026) & (W Units) Table 242. SAMEA Multivalent Vaccines Sales by Country (2027-2032) & (W Units) Table 243. SAMEA Multivalent Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 244. SAMEA Multivalent Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 245. Brazil Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 246. Argentina Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 247. Chile Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 248. Colombia Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 249. Peru Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 250. Saudi Arabia Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 251. Israel Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 252. UAE Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 253. Turkey Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 254. Iran Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 255. Egypt Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Table 256. Key Raw Materials Table 257. Raw Materials Key Suppliers Table 258. Multivalent Vaccines Distributors List Table 259. Multivalent Vaccines Customers List Table 260. Research Programs/Design for This Report Table 261. Authors List of This Report Table 262. Secondary Sources Table 263. Primary Sources List of Figures Figure 1. Multivalent Vaccines Image Figure 2. Global Multivalent Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Toxoid Vaccines Image Figure 5. Live Attenuated Vaccines Image Figure 6. Conjugate Vaccines Image Figure 7. Inactivated and Subunit Vaccines Image Figure 8. Recombinant Vaccines Image Figure 9. Global Multivalent Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Multivalent Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 11. Pediatrics Image Figure 12. Adults Image Figure 13. Global Multivalent Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Multivalent Vaccines Revenue (2021-2032) & (US$ Million) Figure 15. Global Multivalent Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Multivalent Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Multivalent Vaccines Revenue Market Share by Region (2021-2032) Figure 18. Global Multivalent Vaccines Sales (2021-2032) & (W Units) Figure 19. Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 20. Global Multivalent Vaccines Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Multivalent Vaccines Sales YoY (2021-2032) & (W Units) Figure 22. Europe Multivalent Vaccines Sales YoY (2021-2032) & (W Units) Figure 23. China Multivalent Vaccines Sales YoY (2021-2032) & (W Units) Figure 24. Asia (Excluding China) Multivalent Vaccines Sales YoY (2021-2032) & (W Units) Figure 25. South America, Middle East and Africa Multivalent Vaccines Sales YoY (2021-2032) & (W Units) Figure 26. Global Multivalent Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Multivalent Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Multivalent Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Multivalent Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Multivalent Vaccines Revenue Market Share by Type (2021-2032) Figure 32. Global Multivalent Vaccines Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 33. Global Multivalent Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Multivalent Vaccines Sales Market Share by Type (2021-2032) Figure 35. Global Multivalent Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Multivalent Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Multivalent Vaccines Revenue Market Share by Application (2021-2032) Figure 38. Global Multivalent Vaccines Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 39. Global Multivalent Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Multivalent Vaccines Sales Market Share by Application (2021-2032) Figure 41. North America Multivalent Vaccines Revenue Share by Type (2021-2032) Figure 42. North America Multivalent Vaccines Sales Share by Type (2021-2032) Figure 43. North America Multivalent Vaccines Revenue Share by Application (2021-2032) Figure 44. North America Multivalent Vaccines Sales Share by Application (2021-2032) Figure 45. North America Multivalent Vaccines Revenue Share by Country (2021-2032) Figure 46. North America Multivalent Vaccines Sales Share by Country (2021-2032) Figure 47. Europe Multivalent Vaccines Revenue Share by Type (2021-2032) Figure 48. Europe Multivalent Vaccines Sales Share by Type (2021-2032) Figure 49. Europe Multivalent Vaccines Revenue Share by Application (2021-2032) Figure 50. Europe Multivalent Vaccines Sales Share by Application (2021-2032) Figure 51. Europe Multivalent Vaccines Revenue Share by Country (2021-2032) Figure 52. Europe Multivalent Vaccines Sales Share by Country (2021-2032) Figure 53. China Multivalent Vaccines Revenue Share by Type (2021-2032) Figure 54. China Multivalent Vaccines Sales Share by Type (2021-2032) Figure 55. China Multivalent Vaccines Revenue Share by Application (2021-2032) Figure 56. China Multivalent Vaccines Sales Share by Application (2021-2032) Figure 57. Asia Multivalent Vaccines Revenue Share by Type (2021-2032) Figure 58. Asia Multivalent Vaccines Sales Share by Type (2021-2032) Figure 59. Asia Multivalent Vaccines Revenue Share by Application (2021-2032) Figure 60. Asia Multivalent Vaccines Sales Share by Application (2021-2032) Figure 61. Asia Multivalent Vaccines Revenue Share by Country (2021-2032) Figure 62. Asia Multivalent Vaccines Sales Share by Country (2021-2032) Figure 63. SAMEA Multivalent Vaccines Revenue Share by Type (2021-2032) Figure 64. SAMEA Multivalent Vaccines Sales Share by Type (2021-2032) Figure 65. SAMEA Multivalent Vaccines Revenue Share by Application (2021-2032) Figure 66. SAMEA Multivalent Vaccines Sales Share by Application (2021-2032) Figure 67. SAMEA Multivalent Vaccines Revenue Share by Country (2021-2032) Figure 68. SAMEA Multivalent Vaccines Sales Share by Country (2021-2032) Figure 69. Multivalent Vaccines Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Multivalent Vaccines Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Toxoid Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Recombinant Vaccines
Applications
  • Pediatrics
  • Adults
Companies covered
  • Bavarian Nordic (Denmark)
  • CSL Limited (Australia)
  • Daiichi Sankyo (Japan)
  • Emergent BioSolutions, Inc(US)
  • GlaxoSmithKline, plc (U.K.)
  • MedImmune, LLC (US)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Panacea Biotec (India)
  • Protein Sciences Corporation (US)
  • Serum Institute of India Pvt. Ltd. (India)
  • Astellas Pharma Inc. (Japan)
  • Pfizer, Inc(US)
  • Merck & Co., Inc(US)
  • Johnson & Johnson (US)
  • Sanofi Pasteur SA (France)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Multivalent Vaccines Market by Type
  3. 1.2.1 Global Multivalent Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Toxoid Vaccines
  5. 1.2.3 Live Attenuated Vaccines
  6. 1.2.4 Conjugate Vaccines
  7. 1.2.5 Inactivated and Subunit Vaccines
  8. 1.2.6 Recombinant Vaccines
  9. 1.3 Multivalent Vaccines Market by Application
  10. 1.3.1 Global Multivalent Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Pediatrics
  12. 1.3.3 Adults
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Multivalent Vaccines Market Dynamics
  1. 2.1 Multivalent Vaccines Industry Trends
  2. 2.2 Multivalent Vaccines Industry Drivers
  3. 2.3 Multivalent Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Multivalent Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Multivalent Vaccines Revenue by Region
  3. 3.2.1 Global Multivalent Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Multivalent Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global Multivalent Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global Multivalent Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Multivalent Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Multivalent Vaccines Sales by Region
  9. 3.4.1 Global Multivalent Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Multivalent Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global Multivalent Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global Multivalent Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Multivalent Vaccines Revenue by Manufacturers
  2. 4.1.1 Global Multivalent Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Multivalent Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Multivalent Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Multivalent Vaccines Sales by Manufacturers
  6. 4.2.1 Global Multivalent Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Multivalent Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Multivalent Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Multivalent Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Multivalent Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Multivalent Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Multivalent Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global Multivalent Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Multivalent Vaccines Market CR5 and HHI
  16. 4.8.2 2025 Multivalent Vaccines Tier 1, Tier 2, and Tier 3
5 Multivalent Vaccines Market by Type
  1. 5.1 Global Multivalent Vaccines Revenue by Type
  2. 5.1.1 Global Multivalent Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Multivalent Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Multivalent Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Multivalent Vaccines Sales by Type
  6. 5.2.1 Global Multivalent Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Multivalent Vaccines Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Multivalent Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global Multivalent Vaccines Price by Type
6 Multivalent Vaccines Market by Application
  1. 6.1 Global Multivalent Vaccines Revenue by Application
  2. 6.1.1 Global Multivalent Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Multivalent Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Multivalent Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Multivalent Vaccines Sales by Application
  6. 6.2.1 Global Multivalent Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Multivalent Vaccines Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Multivalent Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global Multivalent Vaccines Price by Application
7 Company Profiles
  1. 7.1 Bavarian Nordic (Denmark)
  2. 7.1.1 Bavarian Nordic (Denmark) Company Information
  3. 7.1.2 Bavarian Nordic (Denmark) Business Overview
  4. 7.1.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
  6. 7.1.5 Bavarian Nordic (Denmark) Recent Developments
  7. 7.2 CSL Limited (Australia)
  8. 7.2.1 CSL Limited (Australia) Company Information
  9. 7.2.2 CSL Limited (Australia) Business Overview
  10. 7.2.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
  12. 7.2.5 CSL Limited (Australia) Recent Developments
  13. 7.3 Daiichi Sankyo (Japan)
  14. 7.3.1 Daiichi Sankyo (Japan) Company Information
  15. 7.3.2 Daiichi Sankyo (Japan) Business Overview
  16. 7.3.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
  18. 7.3.5 Daiichi Sankyo (Japan) Recent Developments
  19. 7.4 Emergent BioSolutions, Inc(US)
  20. 7.4.1 Emergent BioSolutions, Inc(US) Company Information
  21. 7.4.2 Emergent BioSolutions, Inc(US) Business Overview
  22. 7.4.3 Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio
  24. 7.4.5 Emergent BioSolutions, Inc(US) Recent Developments
  25. 7.5 GlaxoSmithKline, plc (U.K.)
  26. 7.5.1 GlaxoSmithKline, plc (U.K.) Company Information
  27. 7.5.2 GlaxoSmithKline, plc (U.K.) Business Overview
  28. 7.5.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
  30. 7.5.5 GlaxoSmithKline, plc (U.K.) Recent Developments
  31. 7.6 MedImmune, LLC (US)
  32. 7.6.1 MedImmune, LLC (US) Company Information
  33. 7.6.2 MedImmune, LLC (US) Business Overview
  34. 7.6.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
  36. 7.6.5 MedImmune, LLC (US) Recent Developments
  37. 7.7 Mitsubishi Tanabe Pharma Corporation (Japan)
  38. 7.7.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Information
  39. 7.7.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
  40. 7.7.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
  42. 7.7.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
  43. 7.8 Panacea Biotec (India)
  44. 7.8.1 Panacea Biotec (India) Company Information
  45. 7.8.2 Panacea Biotec (India) Business Overview
  46. 7.8.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
  48. 7.8.5 Panacea Biotec (India) Recent Developments
  49. 7.9 Protein Sciences Corporation (US)
  50. 7.9.1 Protein Sciences Corporation (US) Company Information
  51. 7.9.2 Protein Sciences Corporation (US) Business Overview
  52. 7.9.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
  54. 7.9.5 Protein Sciences Corporation (US) Recent Developments
  55. 7.10 Serum Institute of India Pvt. Ltd. (India)
  56. 7.10.1 Serum Institute of India Pvt. Ltd. (India) Company Information
  57. 7.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
  58. 7.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
  60. 7.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
  61. 7.11 Astellas Pharma Inc. (Japan)
  62. 7.11.1 Astellas Pharma Inc. (Japan) Company Information
  63. 7.11.2 Astellas Pharma Inc. (Japan) Business Overview
  64. 7.11.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
  66. 7.11.5 Astellas Pharma Inc. (Japan) Recent Developments
  67. 7.12 Pfizer, Inc(US)
  68. 7.12.1 Pfizer, Inc(US) Company Information
  69. 7.12.2 Pfizer, Inc(US) Business Overview
  70. 7.12.3 Pfizer, Inc(US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Pfizer, Inc(US) Multivalent Vaccines Product Portfolio
  72. 7.12.5 Pfizer, Inc(US) Recent Developments
  73. 7.13 Merck & Co., Inc(US)
  74. 7.13.1 Merck & Co., Inc(US) Company Information
  75. 7.13.2 Merck & Co., Inc(US) Business Overview
  76. 7.13.3 Merck & Co., Inc(US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio
  78. 7.13.5 Merck & Co., Inc(US) Recent Developments
  79. 7.14 Johnson & Johnson (US)
  80. 7.14.1 Johnson & Johnson (US) Company Information
  81. 7.14.2 Johnson & Johnson (US) Business Overview
  82. 7.14.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
  84. 7.14.5 Johnson & Johnson (US) Recent Developments
  85. 7.15 Sanofi Pasteur SA (France)
  86. 7.15.1 Sanofi Pasteur SA (France) Company Information
  87. 7.15.2 Sanofi Pasteur SA (France) Business Overview
  88. 7.15.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
  90. 7.15.5 Sanofi Pasteur SA (France) Recent Developments
8 North America
  1. 8.1 North America Multivalent Vaccines Market Size by Type
  2. 8.1.1 North America Multivalent Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America Multivalent Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America Multivalent Vaccines Price by Type (2021-2032)
  5. 8.2 North America Multivalent Vaccines Market Size by Application
  6. 8.2.1 North America Multivalent Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America Multivalent Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America Multivalent Vaccines Price by Application (2021-2032)
  9. 8.3 North America Multivalent Vaccines Market Size by Country
  10. 8.3.1 North America Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Multivalent Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Multivalent Vaccines Market Size by Type
  2. 9.1.1 Europe Multivalent Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe Multivalent Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe Multivalent Vaccines Price by Type (2021-2032)
  5. 9.2 Europe Multivalent Vaccines Market Size by Application
  6. 9.2.1 Europe Multivalent Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe Multivalent Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe Multivalent Vaccines Price by Application (2021-2032)
  9. 9.3 Europe Multivalent Vaccines Market Size by Country
  10. 9.3.1 Europe Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Multivalent Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Multivalent Vaccines Market Size by Type
  2. 10.1.1 China Multivalent Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China Multivalent Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China Multivalent Vaccines Price by Type (2021-2032)
  5. 10.2 China Multivalent Vaccines Market Size by Application
  6. 10.2.1 China Multivalent Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China Multivalent Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China Multivalent Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Multivalent Vaccines Market Size by Type
  2. 11.1.1 Asia Multivalent Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia Multivalent Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia Multivalent Vaccines Price by Type (2021-2032)
  5. 11.2 Asia Multivalent Vaccines Market Size by Application
  6. 11.2.1 Asia Multivalent Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia Multivalent Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia Multivalent Vaccines Price by Application (2021-2032)
  9. 11.3 Asia Multivalent Vaccines Market Size by Country
  10. 11.3.1 Asia Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Multivalent Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Multivalent Vaccines Market Size by Type
  2. 12.1.1 SAMEA Multivalent Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Multivalent Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Multivalent Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA Multivalent Vaccines Market Size by Application
  6. 12.2.1 SAMEA Multivalent Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Multivalent Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Multivalent Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA Multivalent Vaccines Market Size by Country
  10. 12.3.1 SAMEA Multivalent Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Multivalent Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Multivalent Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Multivalent Vaccines Value Chain Analysis
  2. 13.1.1 Multivalent Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Multivalent Vaccines Production Mode & Process
  6. 13.2 Multivalent Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Multivalent Vaccines Distributors
  9. 13.2.3 Multivalent Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst